Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 278-284 , March 2007

Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes

Received 25 November 2005 ,Revised 31 May 2006 ,Accepted 5 July 2006.

References 

  1. Hara H, Egusa G, Yamakido M, Kawate R. The high prevalence of diabetes mellitus and hyperinsulinemia among the Japanese–Americans living in Hawaii and Los Angeles. Diab. Res. Clin. Pract. 1994;24(Suppl.):S37–S42
  2. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes. 2002;51:2170–2178
  3. Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia. 1984;26:44–49
  4. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J. Clin. Endocrinol. Metab. 2001;86:4047–4058
  5. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110
  6. Robertson RP, Olson LK, Zhang HJ. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes. 1994;43:1085–1089
  7. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52:581–587
  8. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diab. Care. 1997;20:1539–1542
  9. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J. Clin. Endocrinol. Metab. 2002;87:4171–4176
  10. Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diab. Obes. Metab. 2004;6:384–390
  11. Galloway JA, Chance RE. Improving insulin therapy: achievements and challenges. Horm. Metab. Res. 1994;26:591–598
  12. Anderson JH, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R Multicenter Insulin Lispro Study Group. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin. Ther. 1997;19:62–72
  13. Del Prato S. In search of normoglycaemia in diabetes: controlling postprandial glucose. Int. J. Obes. Relat. Metab. Disord. 2002;26(Suppl. 3):S9–S17
  14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diab. Care 26 (Suppl. 1) (2003) S5–S20.
  15. Japan Diabetes Society . Diabetes Treatment Guide, 2002–2003. Tokyo: Bunkodo; 2002;
  16. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  17. DECODE Study Group, The European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Arch. Intern. Med. 2001;161:397–405
  18. Bastyr EJ, Stuart CA, Brodows RG, et al. IOEZ Study Group Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diab. Care. 2000;23:1236–1241
  19. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diab. Care. 2003;26:881–885
  20. Efanova IB, Zaitsev SV, Zhivotovsky B, et al. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J. Biol. Chem. 1998;273:33501–33507
  21. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab. 2005;90:501–506
  22. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am. J. Med. 2002;113(Suppl. 6A):3S–11S
  23. Proietto J. Mechanisms of insulin resistance caused by nutrient toxicity. Hepatol. Res. 2005;33:87–91
  24. Hawkins M, Rossetti L. Insulin resistance and its role in the pathogenesis of type 2 diabetes. In:  Kahn RC,  Weir GC,  King GL,  Jacobson AM,  Moses AC,  Smith RJ editor. Joslin's Diabetes Mellitus. Philadelphia: Lippincott Williams & Wilkins; 2005;p. 425–448
  25. Zhao H, Yakar S, Gavrilova O, et al. Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes. 2004;53:2901–2909
  26. Henquin J-C. Cell biology of insulin secretion. In:  Kahn RC,  Weir GC,  King GL,  Jacobson AM,  moses AC,  Smith RJ editor. Joslin's Diabetes Mellitus. Philadelphia: Lippincott Williams & Wilkins; 2005;p. 83–107
  27. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes. 1977;26:605–610
  28. Hendriksen C, Faber OK, Drejer J, Binder C. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-petide response to intravenous glucagon. Diabetologia. 1977;13:615–619
  29. Madsbad S, Krarup T, McNair P, et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med. Scand. 1981;210:153–156
  30. Robertson RP. Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes. 2004;53:633–644
  31. Ahren B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur. J. Endocrinol. 2004;150:97–104
  32. Kawamori R, Shichiri M, Kikuchi M, Yamasaki Y, Abe H. Perfect normalization of excessive glucagon responses to intravenous arginine in human diabetes mellitus with the artificial beta-cell. Diabetes. 1980;29:762–765
  33. Hamaguchi T, Fukushima H, Uehara M, et al. Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells. Diabetologia. 1991;34:801–806
  34. Xu E, Kumar M, Zhang Y, et al. Intra-islet insulin suppresses glucagon release via GABA–GABAA receptor system. Cell. Metab. 2006;3:47–58

PII: S0168-8227(06)00336-6

doi: 10.1016/j.diabres.2006.07.019

Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 278-284 , March 2007

Article Tools

* Image Usage & Resolution